Seragon has concluded the pre-clinical study of SRN-901 to assess its effect on aging as well as various health markers
The results showed increased expression of longevity-related genes and decreased expression of aging-related genes in whole-genome transcriptome analysis of over 300 mice with additional favorable changes in biomarkers linked to a younger biological age
Additional tests to assess SRN-901’s effect on health span as well as physical & cognitive function demonstrated increased endurance & improved frailty scores in elderly mice along with reduced tumor occurrence among the treated group. Further analysis continues for additional findings, with results to be published upon completion of supplementary analysis
Ref: Seragon Biosciences | Image: Seragon Biosciences
Related News:- GV20 Therapeutics Collaborates with Merck to Evaluate GV20-0251 + KEYTRUDA in Patients with Advanced Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
